1. R . D. Deshpande, D. V. Gowda, N. Mahammed and D. N. Maramwar, Bi-layer tablets an emerging trend: a review, Int. J. Pharm. Sci. Res. 2 (2011) 2534-2544.
3. A . Divya, K. Kavitha, M. R. Kumar, S. Dakshayani and SD Singh Jagadeesh, Bilayer tablet technology: An overview, J. Appl. Pharm. Sci. 1 (2011) 43-47.
5. Experts in solid dosage discuss the formulation and manufacture of multilayer tablets. Multilayer tablets: Key challenges and trends, Pharm. Technol. 36 (2012) 22-33.
6. U. Conte and L. Maggi, Modulation of the dissolution profiles from Geomatrix(r) multi-layer matrix tablets containing drugs of different solubility, Biomaterials 17 (1996) 889-896; DOI: 10.1016/ 0142-9612(96)83284-4.10.1016/0142-9612(96)83284-4
7. A . Kulkarni and M. Bhatia, Development and evaluation of regioselective bilayer floating tablets of atenolol and lovastatin for biphasic release profile, Iran. J. Pharm. Res. 8 (2009) 15-25.
9. S. B. Bagde, B. V. Bakde, M. Channawar and A. V. Chandewar, Formulation and evaluation of bilayer tablets of metoprolol succinate and ramipril, Int. J. Pharm Pharm. Sci. 3 (2011) 174-178.
10. S. Aryal and N. Skalo-Basnet, Stability of amlodipine besylate and atenolol in multi-component tablets of mon-layer and bi-layer types, Acta Pharm. 58 (2008) 299-308; DOI: 10.2478/v10007-008-0012-5.10.2478/v10007-008-0012-519103566
11. S. R. Vaithiyalingam and V. A. Sayeed, Critical factors in manufacturing multi-layer tablets - Assessing material attributes, in process controls, manufacturing process and product performance, Int. J. Pharm. 398 (2010) 9-13; DOI : 10.1016/j.ijpharm.2010.07.025.10.1016/j.ijpharm.2010.07.02520656000
13. F. Eisenacher, A. Schadlich and K. Mader, Monitoring of internal pH gradients within multi-layer tablets by optical methods and EPR imaging, Int. J. Pharm. 417 (2011) 204-215; DOI : 10.1016/j.ijpharm. 2010.10.010.
15. J. A. Mollica, C. R. Rohm, J. B. Smith and H. R. Govan, Hydrolysis of benzothiadiazines, J. Pharm. Sci. 6 (1971) 1380-1384; DOI: 10.1002/jps.2600600920.10.1002/jps.26006009205567589
17. S. I. F. Badaway and M. A. Hussain, Microenvironmental pH modulation in solid dosage forms, J. Pharm. Sci. 96 (2007) 948-959; DOI: 10.1002/jps.20932.10.1002/jps.2093217455349
18. K . Moodly, V. Pillay, Y. E. Choonara, L. C. du Toit, V. M. K. Ndesendo, P. Kumar, S. Cooppan and P. Bawa, Oral drug delivery systems comprising altered geometric configurations for controlled release drug delivery, Int. J. Mol. Sci. 13 (2012) 18-43; DOI : 10.3390/ijms13010018.10.3390/ijms13010018326967022312236
19. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Guideline on the Investigation of Bioequivalence, London, 20 January 2010; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
20. A . N. Elmeshad and M. K. Darwish, Stability studies of the effect of crosslinking on hydrochlorothiazide release, Drug Dis. Ther. 3 (2009) 136-142.
21. C. R. Rehm and J. B. Smith, The photometric determination of hydrochlorothiazide and its hydrolysis product, J. Am. Pharm. Assoc. Am. Pharm. Assoc. 49 (1960) 386-389.10.1002/jps.303049061713854484
22. A . Crouter and L. Briens, The effect of moisture on the flowability of pharmaceutical excipients, AAPS PharmSciTech. 15 (2014) 65-74; DOI: 10.1208/s12249-013-0036-0.10.1208/s12249-013-0036-0390915624092523